Multiple sclerosis (MS) is an inflammatory, demyelinating, and neurodegenerative disease
of the central nervous system of uncertain etiology. There is consensus that a dysregulated …

The era of disease-modifying drugs (DMDs) in multiple sclerosis (MS) treatment began in
the 1990s, first with interferon-β (IFNβ), and the number of agents has increased steadily …

We reviewed the records of 391 patients who had presented with a Clinically Isolated
Syndrome and selected 205 who had performed a baseline spinal tap and MRI scan. We …

Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system,
usually occurring in young adults and leading to disability. Despite the progress in …

Objective To determine the best method to measure intrathecal immunoglobulin (Ig) M
synthesis (ITMS), a biomarker of worse prognosis in multiple sclerosis (MS). We compared …

MicroRNAs (miRNAs) have recently emerged as a new class of modulators of gene
expression. miRNAs control protein synthesis by targeting mRNAs for translational …

Multiple sclerosis (MS) is an immune-mediated inflammatory and degenerative disorder of
the central nervous system (CNS) with heterogeneous clinical manifestations. In the last …

Oligoclonal IgM bands (OCMB) against myelin lipids predict an aggressive multiple sclerosis
(MS) course. However, the clinical significance of OCMB without lipid specificity, present in …

Background The possibility to better predict the severity of the disease in a patient newly
diagnosed with multiple sclerosis would allow the treatment strategy to be personalized and …

Background: Cerebrospinal fluid (CSF) kappa free light chains (KFLC) are gaining
increasing interest as markers of intrathecal immunoglobulin synthesis. The main aim of this …